Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...

Novo Holdings in February agreed to buy Catalent to boost output of the popular weight-loss drug Wegovy. According to the ...

Novo Nordisk's (NVO) acquisition of three Catalent (CTLT) production sites to close soon as its parent wins regulatory nod ...

After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to ...

Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to ...

Novo Holdings is on track to acquire Catalent, a global contract development and manufacturing organization, in a $16.5 ...

Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...

Catalent (CTLT) stock rises on reports of imminent $16.5 billion sale to Novo Holdings with FTC approval and EU Commission ...

Novo Holdings has completed regulatory conditions for its $16.5 billion acquisition of Catalent, aiming to increase production of Wegovy, a weight-loss drug. The deal includes selling three Catalent ...

Catalent Inc. (CTLT) and Novo Holdings A/S announced that the companies have fulfilled all regulatory closing conditions for their ...

Catalent, Inc. ("Catalent," NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences ...

Find insight on Novo Holdings, Malaysian glove sector and more in the latest Market Talks covering health care.